688161 Shandong Weigao Orthopaedic Device
- 26.38
- +0.08+0.30%
Shandong Weigao Orthopaedic Device News
Weigao Orthopedic (688161.SH): A total of 0.399% of shares have been repurchased
Gelonghui, May 6, 丨 Weigao Orthopedics (688161.SH) announced that as of April 30, 2024, the company had repurchased a total of 1,597,266 shares through the Shanghai Stock Exchange trading system, accounting for 0.399% of the company's total share capital of 400,000,000.00 shares. The highest price of the repurchase transaction was 42.40 yuan/share, the lowest price was 28.59 yuan/share, and the total amount of capital paid was RMB 57,460,342.24 (excluding transaction fees).
Weigao Orthopedic Clinic (688161): Short-term performance is under pressure, innovation drives to a new peak
Incident: Weigao Orthopedic released its report for the first quarter of 2024 on April 30, 2024: The company achieved revenue of 348 million yuan in the first quarter of 2024, a year-on-year decrease of 10.74%; realized net profit of 35 million yuan
Weigao Co., Ltd. (01066): Weigao Orthopedic (688161.SH)'s net profit of 34.9057 million yuan in the first quarter decreased by 62.92% year-on-year
Weigao Co., Ltd. (01066) announced Weigao Orthopedic (688161.SH) results for the first quarter of 2024, business...
League of Nations Securities: The impact of collection is gradually clear, and the localization rate of the orthopedic industry continues to rise
Orthopedics is expected to usher in restorative growth
Guoxin Securities released a research report on April 9 stating that it gave Weigao Orthopedic (688161.SH) an increase in its holdings. The main reasons for the rating include: 1) the 2023 performance was affected by falling factory prices and channel inv
Guoxin Securities released a research report on April 9 stating that it gave Weigao Orthopedic (688161.SH) an increase in its holdings. The main reasons for the rating include: 1) the 2023 performance was affected by falling factory prices and channel inventory compensation due to volume procurement execution; 2) revenue from each business line was under varying degrees of pressure, and sports medicine and tissue repair products became an important source of revenue; 3) gross net margin declined, and sales and R&D expenses increased significantly; 4) R&D investment remained high, and many products were in the registration stage. (Mainichi Keizai Shimbun)
Weigao Orthopedics (688161) 2023 Performance Review: Short-term performance is under pressure, the company actively optimizes product structure
Incident: The company released its annual results report for the year 23, achieving revenue of 1,284 billion yuan (-37.6%) for the whole year, achieving net profit of 112 million yuan (-81.3%) attributable to shareholders of listed companies, and deducting non-recurring profit and loss
Weigao Orthopedics (688161) Science and Technology Innovation Board Company Dynamic Research: Gathering gaps ended, performance entered an upward channel
Incident: On March 27, 2024, Weigao Orthopedic issued the 2023 annual results announcement: The company achieved revenue of 1,284 billion yuan in 2023, a year-on-year decrease of 37.63%. Achieved net profit of 112 million yuan to mother
Earnings Troubles May Signal Larger Issues for Shandong Weigao Orthopaedic Device (SHSE:688161) Shareholders
The subdued market reaction suggests that Shandong Weigao Orthopaedic Device Co., Ltd's (SHSE:688161) recent earnings didn't contain any surprises. However, we believe that investors should be aware
Weigao Orthopedic (688161.SH) has spent 574.603 million yuan to buy back 1,597,300 shares
Zhitong Finance App News, Weigao Orthopedics (688161.SH) announced that as of March 31, 2024, the company had repurchased a total of 1,597,300 shares of the company's shares through the Shanghai Stock Exchange trading system, accounting for 0.399% of the company's total share capital. The highest price of the repurchase transaction was 42.40 yuan/share, the lowest price was 28.59 yuan/share, and the total amount of capital paid was RMB 574.603 million (excluding transaction fees).
Weigao Orthopedics (688161): Performance under pressure from collection, optimistic about the company's platform-based development
Incident: In 2023, the company achieved revenue of 1,284 million yuan (-37.63%, same period below), net profit of 112 million yuan (-81.30%) to mother, net profit of 108 million yuan (-81 million yuan) after deducting net profit of non-return to mother
Weigao Orthopedics (688161): Performance is under pressure due to disrupted procurement, optimistic about the long-term development trend of leading orthopedic surgeons
Performance was pressured by orthopedic collection, and the company actively responded to the continuous improvement of the quality of operations. After the implementation of volume procurement of orthopedic products, the company's 2023 performance was under pressure due to reduced procurement prices and channel inventory compensation, achieving revenue of 12.8
Weigao Orthopaedic Device Names Chairman
Shandong Weigao Orthopaedic Device (SHA:688161) appointed one of its directors, Chen Min, as chairman, the company said in its disclosure on the Shanghai Stock Exchange. The company's board of directo
Weigao Orthopedic (688161.SH): Net profit in 2023 fell 81.3% year on year, and plans to pay 10 to 1.2 yuan
On March 26, Ge Longhui Orthopedics (688161.SH) released its 2023 annual report. During the reporting period, it achieved operating income of 1,284 million yuan, a year-on-year decrease of 37.63%; net profit attributable to shareholders of listed companies was 112 million yuan, a year-on-year decrease of 81.68%; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 108 million yuan, a year-on-year decrease of 81.68%; and basic earnings per share were 0.28 yuan. The company plans to distribute a cash dividend of 1.20 yuan (tax included) for every 10 shares to all shareholders.
Weigao Orthopaedic Device's Chairman Resigns
Shandong Weigao Orthopaedic Device's (SHA:688161) chairman, Gong Jianbo, resigned due to personal reasons, according to the company's filing published Saturday on the Shanghai Stock Exchange. Long Jin
Weigao Orthopedic Clinic (688161.SH): Chairman and Director Gong Jianbo Resigns
On March 8, Gelonghui Orthopedic Clinic (688161.SH) announced that the company's board of directors received a written application for resignation from the company's chairman, Mr. Gong Jianbo, on March 8. Due to personal reasons, Mr. Gong Jianbo requested his resignation as a director, chairman of the third board of directors, and a member of the relevant special committee of the board of directors. After his resignation, Mr. Gong Jianbo will no longer hold any position in the company or its subsidiaries. Mr. Gong Jianbo will continue to provide valuable opinions and suggestions for the company's future development as a consultant and shareholder of the company. Due to job adjustments, Ms. Yan Xia applied to resign as a director of the third board of directors of the company. After her resignation, Ms. Yan Xia was no longer there
Express News | Weigao Orthopedics: Due to personal reasons, Mr. Gong Jianbo requested his resignation as a director of the 3rd board of directors, and a member of the relevant special committee of the board of directors; due to job adjustments, Ms. Yan Xia applied to re
The Returns On Capital At Shandong Weigao Orthopaedic Device (SHSE:688161) Don't Inspire Confidence
What are the early trends we should look for to identify a stock that could multiply in value over the long term? Firstly, we'd want to identify a growing return on capital employed (ROCE) and then a
Weigao Orthopedic (688161.SH) has repurchased a total of 1,597,300 shares at a cost of 574.603 million yuan
Weigao Orthopedic (688161.SH) issued an announcement. As of February 29, 2024, the company approved Shanghai Securities...
Weigao Orthopedic Clinic (688161.SH): There is currently no brain-computer interface-related layout
Gelonghui, Feb. 29丨Weigao Orthopedics (688161.SH) said on the investor interactive platform that the company currently has no brain-computer interface-related layout.
Weigao Orthopedic (688161.SH) performance report: 2023 net profit of 112 million yuan fell 81.29% year on year
On February 28, Ge Longhui Orthopedics (688161.SH) announced the 2023 Annual Results Report. During the reporting period, the company achieved total operating revenue of 1,284 million yuan, down 37.61% from the same period last year; net profit attributable to owners of the parent company was 112 million yuan, down 81.29% from the same period last year.
Analysis
Price Target
No Data
